Tailoring Treatment in Colorectal Cancer

Recruiting now

Conditions studied: Colorectal Neoplasms

In brief

In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients. With this, the investigators aim to develop a novel predictive biomarker of immunotherapy response, by testing combinations of chemotherapies and chimeric antigen receptor (CAR) T cells. Critically, this affects a large subgroup of patients currently not considered to benefit from such treatment. To support the hypothesis, the project will make use of cutting-edge, cell-based functional diagnostics. Individual patients' cancer cells will be screened against a panel of chemotherapies and targeted therapies including CAR T cells, to assess the optimal combination of therapies to induce immunotherapy efficacy in otherwise unresponsive CRC.

Key facts

Study ID

NCT05401318

Run by

University Hospital, Akershus

People needed

40

Starts

2022-03-28

Expected to finish

2027-01-01

Last updated by the study team

2024-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed colorectal cancer scheduled for curative surgery and standard clinical follow-up.

You may not qualify if…

• Unable/unwilling to sign the informed consent form.

Where it is running

• Akershus University Hospital — Lørenskog, Akershus, Norway (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.